Skip to main content
Only goal: Enable you next research experiment
ENZOLIFE SCIENCES

Gene Technologies — Enzo Therapeutics

Enzo Therapeutics gene technologies — nucleic acid platforms, AMPIVIEW diagnostics, and SENTINEL molecular beacons

Gene Technologies

Pioneering nucleic acid technologies translated from research tools to therapeutic platforms. Enzo’s foundational patents in nucleic acid labeling, modification, and detection power next-generation gene therapies and companion diagnostics.

From Research Pioneer to Therapeutic Innovator

Enzo Life Sciences was among the first companies to develop non-radioactive nucleic acid labeling and detection technologies — innovations that fundamentally transformed molecular biology. Today, this deep expertise in nucleic acid chemistry is being translated into therapeutic applications. Our proprietary modified nucleotides, delivery platforms, and diagnostic technologies address critical challenges in gene therapy development including stability, cellular uptake, target specificity, and patient monitoring.

Nucleic Acid Therapeutics

Proprietary modified nucleotides and labeling chemistries enabling enhanced stability, cellular uptake, and target specificity for antisense oligonucleotides (ASOs) and siRNA therapeutics. Enzo’s chemical modifications improve nuclease resistance and reduce immunogenicity, extending therapeutic duration and enabling lower dosing regimens.

ASO/siRNA

Gene Delivery Systems

Novel delivery platforms leveraging Enzo’s nucleic acid modification expertise for improved gene therapy vector design and non-viral delivery approaches. Our technologies support both viral vector optimization (AAV, lentiviral) and lipid nanoparticle-based delivery systems with enhanced tissue targeting capabilities.

Delivery

AMPIVIEW® Diagnostic Platform

RNA visualization technology with single-molecule sensitivity for therapeutic monitoring applications. AMPIVIEW enables real-time detection and quantification of gene expression at the individual cell level, providing a powerful companion diagnostic platform for gene therapy programs and patient stratification.

Diagnostics

SENTINEL® Molecular Beacons

Proprietary molecular beacon technology for real-time monitoring of nucleic acid therapeutics in cellular and tissue settings. SENTINEL probes provide critical pharmacokinetic and pharmacodynamic data for gene therapy development, enabling researchers to track therapeutic nucleic acid biodistribution and activity in vivo.

Monitoring

Gene Technologies — By the Numbers

100+
Nucleic Acid Patents
25+
Modified Nucleotide Chemistries
5000+
Gene Therapy Citations
10+
Diagnostic Applications

Advance Your Gene Therapy Program

Connect with our business development team to explore licensing, co-development, and technology transfer opportunities across our therapeutic platforms.

Join & Get 15% Off

Sign up for exclusive offers, original stories, events and more.

Learn more →